Publications
2024
Scholarly publications
van Hattem, C. C., de Jong, A. J., de Groot, J. S., Hoekman, J., Broekman, K. E., Sonke, G. S., van Hennik, P. B., & Bloem, L. T. (2024). Factors affecting the feasibility of post-authorisation RCTs for conditionally authorised anticancer medicines: a multistakeholder perspective from a qualitative focus group study. BMJ Open, 14, Article e084483. https://doi.org/10.1136/bmjopen-2024-084483
Hogervorst, M. A., van Hattem, C. C., Sonke, G. S., Mantel-Teeuwisse, A. K., Goettsch, W. G., & Bloem, L. T. (2024). Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned. Drug Discovery Today, 29(7), Article 104031. https://doi.org/10.1016/j.drudis.2024.104031
2023
Scholarly publications
Zheng, Y., Prince, N., Hattem, C. V., Garssen, J., Pardo, P. P., & Kraneveld, A. D. (2023). The interaction between intestinal bacterial metabolites and phosphatase and tensin homolog in autism spectrum disorder. Molecular and Cellular Neuroscience, 124(March 2023), Article 103805. https://doi.org/10.1016/j.mcn.2022.103805
https://dspace.library.uu.nl/bitstream/handle/1874/435527/1-s2.0-S1044743122001117-main.pdf?sequence=1
https://dspace.library.uu.nl/bitstream/handle/1874/435527/1-s2.0-S1044743122001117-main.pdf?sequence=1
Professional publications
Gort, J., van Hattem, C. C., Bloem, L. T., & ten Ham, R. M. T. (2023). Geneesmiddelen voor Geavanceerde Therapie (ATMP’s) in Nederland: Veldverkenning, Knelpuntanalyse en Activiteitenkaart. Utrecht University. https://doi.org/10.33540/1874/433501
Other output
van Hattem, C. C., de Jong, A., de Groot, J. S., & Bloem, L. T. (2023). Feasibility of post-authorization randomized controlled trials for conditionally authorized anticancer medicines-A multistakeholder perspective. Pharmacoepidemiology and Drug Safety, 32, 623-623.